TREM2 shedding by cleavage at the H157-S158 bond is accelerated for the Alzheimer's disease-associated H157Y variant

EMBO Molecular Medicine

Volumn 9, Issue 10, 2017, Pages 1366-1378

  Thornton, Peter ^a   Sevalle, Jean ^b   Deery, Michael J ^c   Fraser, Graham ^a   Zhou, Ye ^b   Ståhl, Sara ^d   Franssen, Elske H ^a   Dodd, Roger B ^e,f   Qamar, Seema ^e   Gomez Perez Nievas, Beatriz ^a   Nicol, Louise SC ^f   Eketjäll, Susanna ^g   Revell, Jefferson ^f   Jones, Clare ^f   Billinton, Andrew ^a   St George Hyslop, Peter H ^b,e   Chessell, Iain ^a   Crowther, Damian C ^a  

^a ASTRAZENECA   (United Kingdom)

^b UNIVERSITY OF TORONTO   (Canada)

^c UNIVERSITY OF CAMBRIDGE   (United Kingdom)

^d KAROLINSKA INSTITUTE   (Sweden)

^e UNIVERSITY OF CAMBRIDGE   (United Kingdom)

^f MEDIMMUNE LTD   (United Kingdom)

^g ASTRAZENECA R AND D   (Sweden)

Author keywords

genetic risk; microglia; neurodegeneration; neuroinflammation

Indexed keywords

ADAM10 ENDOPEPTIDASE; GELATINASE A; GELATINASE B; TRIGGERING RECEPTOR EXPRESSED ON MYELOID CELLS 2; ADAM10 PROTEIN, HUMAN; ADAM17 PROTEIN, HUMAN; CHOLESTEROL DERIVATIVE; G1268267X; IMMUNOGLOBULIN RECEPTOR; MATRIX METALLOPROTEINASE INHIBITOR; MEMBRANE PROTEIN; SECRETASE; SMALL INTERFERING RNA; TREM2 PROTEIN, HUMAN; TUMOR NECROSIS FACTOR ALPHA CONVERTING ENZYME;

ALZHEIMER DISEASE; AMINO TERMINAL SEQUENCE; ANIMAL CELL; ARTICLE; CELL FRACTIONATION; CONTROLLED STUDY; DEGLYCOSYLATION; GENETIC VARIABILITY; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; MOUSE; NONHUMAN; PEPTIDOMICS; PERIPHERAL BLOOD MONONUCLEAR CELL; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN CLEAVAGE; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN SYNTHESIS; PROTEIN SYNTHESIS REGULATION; ANIMAL; C57BL MOUSE; CONDITIONED MEDIUM; GENETICS; HEK293 CELL LINE; MACROPHAGE; METABOLISM; MICROGLIA; NEWBORN; PRIMARY CELL CULTURE; PROTEIN DEGRADATION;

ADAM10 PROTEIN; ADAM17 PROTEIN; ALZHEIMER DISEASE; AMYLOID PRECURSOR PROTEIN SECRETASES; ANIMALS; ANIMALS, NEWBORN; CULTURE MEDIA, CONDITIONED; HEK293 CELLS; HUMANS; KETOCHOLESTEROLS; MACROPHAGES; MATRIX METALLOPROTEINASE INHIBITORS; MEMBRANE GLYCOPROTEINS; MEMBRANE PROTEINS; MICE; MICE, INBRED C57BL; MICROGLIA; PRIMARY CELL CULTURE; PROTEOLYSIS; RECEPTORS, IMMUNOLOGIC; RNA, SMALL INTERFERING;

EID: 85030266335     PISSN: 17574676     EISSN: 17574684     Source Type: Journal    
DOI: 10.15252/emmm.201707673     Document Type: Article

References (32)

1. Caescu CI, Jeschke GR, Turk BE (2009) Active-site determinants of substrate recognition by the metalloproteinases TACE and ADAM10. Biochem J 424: 79–88
2. Colonna M (2003) TREMs in the immune system and beyond. Nat Rev Immunol 3: 445–453
3. Finelli D, Rollinson S, Harris J, Jones M, Richardson A, Gerhard A, Snowden J, Mann D, Pickering-Brown S (2015) TREM2 analysis and increased risk of Alzheimer's disease. Neurobiol Aging 36: 546.e9–13
4. Ghani M, Sato C, Kakhki EG, Gibbs JR, Traynor B, St George-Hyslop P, Rogaeva E (2016) Mutation analysis of the MS4A and TREM gene clusters in a case–control Alzheimer's disease data set. Neurobiol Aging 42: 217.e7–217.e13
5. Guerreiro R, Wojtas A, Bras J, Carrasquillo M, Rogaeva E, Majounie E, Cruchaga C, Sassi C, Kauwe JSK, Younkin S et al (2013) TREM2 variants in Alzheimer's disease. N Engl J Med 368: 117–127
6. Hakola HP (1972) Neuropsychiatric and genetic aspects of a new hereditary disease characterized by progressive dementia and lipomembranous polycystic osteodysplasia. Acta Psychiatr Scand Suppl 232: 1–173
7. Hakola HP, Iivanainen M (1973) A new hereditary disease with progressive dementia and polycystic osteodysplasia: neuroradiological analysis of seven cases. Neuroradiology 6: 162–168
8. Hamerman JA, Tchao NK, Lowell CA, Lanier LL (2005) Enhanced Toll-like receptor responses in the absence of signaling adaptor DAP12. Nat Immunol 6: 579–586
9. Hamerman JA, Jarjoura JR, Humphrey MB, Nakamura MC, Seaman WE, Lanier LL (2006) Cutting edge: inhibition of TLR and FcR responses in macrophages by triggering receptor expressed on myeloid cells (TREM)-2 and DAP12. J Immunol 177: 2051–2055
10. Heslegrave A, Heywood W, Paterson R, Magdalinou N, Svensson J, Johansson P, Öhrfelt A, Blennow K, Hardy J, Schott J et al (2016) Increased cerebrospinal fluid soluble TREM2 concentration in Alzheimer's disease. Mol Neurodegener 11: 3
11. + inflammatory macrophages and ameliorates pathology in Alzheimer's disease mouse models. J Exp Med 212: 287–295
12. Jay TR, Hirsch AM, Broihier ML, Miller CM, Neilson LE, Ransohoff RM, Lamb BT, Landreth GE (2017) Disease progression-dependent effects of TREM2 deficiency in a mouse model of Alzheimer's disease. J Neurosci 37: 637–647
13. Jiang T, Tan L, Chen Q, Tan M-SS, Zhou J-SS, Zhu X-CC, Lu H, Wang H-FF, Zhang Y-DD, Yu J-TT (2016) A rare coding variant in TREM2 increases risk for Alzheimer's disease in Han Chinese. Neurobiol Aging 42: 217.e1–217.e3
14. Jonsson T, Stefansson H, Steinberg S, Jonsdottir I, Jonsson PV, Snaedal J, Bjornsson S, Huttenlocher J, Levey AI, Lah JJ et al (2013) Variant of TREM2 associated with the risk of Alzheimer's disease. N Engl J Med 368: 107–116
15. Jonsson T, Stefansson K (2013) TREM2 and neurodegenerative disease. N Engl J Med 369: 1568–1569
16. Kawabori M, Kacimi R, Kauppinen T, Calosing C, Kim JY, Hsieh CL, Nakamura MC, Yenari MA (2015) Triggering receptor expressed on myeloid cells 2 (TREM2) deficiency attenuates phagocytic activities of microglia and exacerbates ischemic damage in experimental stroke. J Neurosci 35: 3384–3396
17. Keren-Shaul H, Spinrad A, Weiner A, Matcovitch-Natan O, Dvir-Szternfeld R, Ulland TK, David E, Baruch K, Lara-Astaiso D, Toth B et al (2017) A unique microglia type associated with restricting development of Alzheimer's disease. Cell 169: 1276–1290
18. Kleinberger G, Yamanishi Y, Suárez-Calvet M, Czirr E, Lohmann E, Cuyvers E, Struyfs H, Pettkus N, Wenninger-Weinzierl A, Mazaheri F et al (2014) TREM2 mutations implicated in neurodegeneration impair cell surface transport and phagocytosis. Sci Transl Med 6: 243ra86
19. Klünemann HH, Ridha BH, Magy L, Wherrett JR, Hemelsoet DM, Keen RW, De Bleecker JL, Rossor MN, Marienhagen J, Klein HE et al (2005) The genetic causes of basal ganglia calcification, dementia, and bone cysts: DAP12 and TREM2. Neurology 64: 1502–1507
20. Li C, Pazgier M, Li J, Li C, Liu M, Zou G, Li Z, Chen J, Tarasov SG, Lu W-Y et al (2010) Limitations of peptide retro-inverso isomerization in molecular mimicry. J Biol Chem 285: 19572–19581
21. Paloneva J, Kestilä M, Wu J, Salminen A, Böhling T, Ruotsalainen V, Hakola P, Bakker AB, Phillips JH, Pekkarinen P et al (2000) Loss-of-function mutations in TYROBP (DAP12) result in a presenile dementia with bone cysts. Nat Genet 25: 357–361
22. Park J-S, Ji IJ, An HJ, Kang M-J, Kang S-W, Kim D-H, Yoon S-Y (2015) Disease-associated mutations of TREM2 alter the processing of N-linked oligosaccharides in the golgi apparatus. Traffic 16: 510–518
23. Piccio L, Deming Y, Del-Águila JL, Ghezzi L, Holtzman DM, Fagan AM, Fenoglio C, Galimberti D, Borroni B, Cruchaga C (2016) Cerebrospinal fluid soluble TREM2 is higher in Alzheimer disease and associated with mutation status. Acta Neuropathol 131: 925–933
24. Slattery CF, Beck JA, Harper L, Adamson G, Abdi Z, Uphill J, Campbell T, Druyeh R, Mahoney CJ, Rohrer JD et al (2014) R47H TREM2 variant increases risk of typical early-onset Alzheimer's disease but not of prion or frontotemporal dementia. Alzheimers Dement 10: 602–608.e4
25. Suárez-Calvet M, Araque Caballero MÁ, Kleinberger G, Bateman RJ, Fagan AM, Morris JC, Levin J, Danek A, Ewers M, Haass C et al (2016a) Early changes in CSF sTREM2 in dominantly inherited Alzheimer's disease occur after amyloid deposition and neuronal injury. Sci Transl Med 8: 369ra178
26. Suárez-Calvet M, Kleinberger G, Araque Caballero MÁ, Brendel M, Rominger A, Alcolea D, Fortea J, Lleó A, Blesa R, Gispert JD et al (2016b) sTREM2 cerebrospinal fluid levels are a potential biomarker for microglia activity in early-stage Alzheimer's disease and associate with neuronal injury markers. EMBO Mol Med 8: 466–476
27. Takahashi K, Rochford CDP, Neumann H (2005) Clearance of apoptotic neurons without inflammation by microglial triggering receptor expressed on myeloid cells-2. J Exp Med 201: 647–657
28. Taylor M, Moore S, Mayes J, Parkin E, Beeg M, Canovi M, Gobbi M, Mann DM, Allsop D (2010) Development of a proteolytically stable retro-inverso peptide inhibitor of beta-amyloid oligomerization as a potential novel treatment for Alzheimer's disease. Biochemistry 49: 3261–3272
29. Wang Y, Cella M, Mallinson K, Ulrich JD, Young KL, Robinette ML, Gilfillan S, Krishnan GM, Sudhakar S, Zinselmeyer BH et al (2015) TREM2 lipid sensing sustains the microglial response in an Alzheimer's disease model. Cell 160: 1061–1071
30. Wunderlich P, Glebov K, Kemmerling N, Tien NT, Neumann H, Walter J (2013) Sequential proteolytic processing of the triggering receptor expressed on myeloid cells-2 (TREM2) protein by ectodomain shedding and γ-secretase-dependent intramembranous cleavage. J Biol Chem 288: 33027–33036
31. Xing J, Titus AR, Humphrey MB (2015) The TREM2-DAP12 signaling pathway in Nasu-Hakola disease: a molecular genetics perspective. Res Rep Biochem 5: 89–100
32. Yuan P, Condello C, Keene CD, Wang Y, Bird TD, Paul SM, Luo W, Colonna M, Baddeley D, Grutzendler J (2016) TREM2 haplodeficiency in mice and humans impairs the microglia barrier function leading to decreased amyloid compaction and severe axonal dystrophy. Neuron 90: 724–739